MigrainesMigraines https://www.omofmedicine.org/wp-content/themes/corpus/images/empty/thumbnail.jpg 150 150 admin https://secure.gravatar.com/avatar/02783426f55984345fb7446817a2af1b?s=96&d=mm&r=g
Key Research Findings
- The frequency of migraine headache was decreased with medical marijuana use.
- “Overall, 85.1% had decreased migraine frequency, with 39.7% reporting positive effects: prevention of or reduced headache frequency (19.8%) or aborted headache (11.6%)
Clinical endocannabinoid deficiency reconsidered: current research supports the theory in migraine, fibromyalgia, irritable bowel, and other treatment-resistant syndromes.(2016)
- What if endocannabinoid levels are too low? It has been theorized that numerous mysterious disorders fit the description of “clinical endocannabinoid deficiency” (CED). Noteworthy among these are migraine, fibromyalgia and idiopathic bowel syndrome (IBS or “spastic colon”).
- The three conditions tend to affect the same individuals at various times of their lives, and are therefore termed “co-morbid.”
- All three are characterized by “central sensitization,” the concept that normal sensations in the brain are magnified to the point of becoming painful when they would not be to a person free from the affliction. The three disorders also benefit from treatment with cannabinoids according to patient testimonials.
- “…cannabinoids reduced pain intensity among migraine patients by 43.5%. The same results were seen in cluster headache patients…”
- “The study confirms that a dysfunction of the endocannabinoid system may contribute to the development of migraine attacks and that a pharmacological modulation of CB receptors can be useful for the treatment of migraine pain.”